Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.29

€1.29

3.940%
0.049
3.940%
€6.24
 
14:57 / Tradegate WKN: A1W025 / Symbol: BLUE / Name: bluebird bio / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Bluebird Bio Inc. Stock

Bluebird Bio Inc. dominated the market today, gaining €0.049 (3.940%).
With 6 Buy predictions and 5 Sell predictions the community is currently undecided on Bluebird Bio Inc..
Based on the current price of 1.29 € the target price of 6 € shows a potential of 364.58% for Bluebird Bio Inc. which would more than double the current price.

Pros and Cons of Bluebird Bio Inc. in the next few years

Pros
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Bluebird Bio Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Bluebird Bio Inc. 3.940% -3.943% -22.344% -70.225% -0.321% -95.158% -
Ironwood Pharmaceuticals 2.600% -3.049% -42.391% -20.785% -23.558% -11.667% -31.701%
Novocure Ltd 9.220% 7.378% -10.971% -75.204% -6.200% -87.619% -
Iovance Biotherapeutics Inc. 1.540% -4.442% -19.187% 128.293% 66.688% -47.104% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-09

When initially glancing at the financials of bluebird bio (NASDAQ: BLUE), a company in the competitive Biotechnology & Medical Research industry, certain key figures immediately stand out. It's apparent that BLUE is in a challenging phase with a net income in the negative, indicating sustained losses over the analyzed periods. The consistent negative cash flow from operating activities suggests that the company's core operations are not yet profitable or self-sustaining. However, the company remains solvent with a notable amount of cash and short-term investments that ostensibly provide liquidity to fund ongoing research and development activities.

General Impressions of the Financials:

The broad financial health of bluebird bio raises some concerns, with the income statements highlighting a pattern of losses. Research and development expenses, common in the biotech sector where the development cycle is long and expensive, dominate their costs. Despite this, there are growth signals present, such as the reported quarterly revenue growth YOY (year over year), suggesting some progression in their operations.

Comments

Prediction Sell
Perf. (%) -2.86%
Target price 0.940
Change
Ends at 05.03.25

bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at HSBC Holdings plc from $2.31 to $1.02. They now have a "reduce" rating on the stock.
Ratings data for BLUE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 3.28%
Target price 4.553
Change
Ends at 21.12.24

bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Bank of America Co. from $12.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for BLUE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -49.75%
Target price 6.486
Change
Ends at 12.12.24

bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Robert W. Baird from $10.00 to $7.00. They now have an "outperform" rating on the stock.
Ratings data for BLUE provided by MarketBeat
Show more